Walleye Trading
ESPR

Walleye Trading’s Esperion Therapeutics ESPR Stock Holding History

Walleye Trading’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,593
Closed -$34.5K – 4117
2026
Q1 		$34.5K Buy
12,593
+8,730
+226% +$27.6K ﹤0.01% 3769
2025
Q4 		$14.3K Buy
+3,863
New +$12.5K ﹤0.01% 4135
2022
Q4 		– Sell
-14,170
Closed -$101K – 5070
2022
Q3 		$95K Buy
+14,170
New +$97.3K ﹤0.01% 4068
2022
Q1 		– Sell
-166,549
Closed -$714K – 5465
2021
Q4 		$833K Buy
166,549
+96,225
+137% +$770K ﹤0.01% 2413
2021
Q3 		$847K Buy
+70,324
New +$1.02M ﹤0.01% 2392
2019
Q3 		– Sell
-2,886
Closed -$114K – 4126
2019
Q2 		$134K Buy
2,886
+1,789
+163% +$84K ﹤0.01% 3176
2019
Q1 		$44K Sell
1,097
-905
-45% -$40.6K ﹤0.01% 3762
2018
Q4 		$92K Buy
+2,002
New +$96.5K ﹤0.01% 3924

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Walleye Trading's ESPR Position: Q2 2026 in Review

Walleye Trading sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 12,593 shares — an estimated $34.5K sold.

Walleye Trading first reported a position in ESPR in Q4 2018 and held it in 8 quarters. The position peaked at $847K in Q3 2021. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Walleye Trading reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Trading sold 12,593 Esperion Therapeutics shares in Q2 2026, an estimated $34.5K.
  • Walleye Trading first reported a position in Esperion Therapeutics in Q4 2018 and held it in 8 quarters.
  • Walleye Trading's Esperion Therapeutics position peaked at $847K in Q3 2021.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.